MGTX - MeiraGTx Holdings plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.19
-0.52 (-2.94%)
As of 11:10AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close17.71
Open17.91
Bid17.22 x 900
Ask17.36 x 1200
Day's Range16.89 - 17.93
52 Week Range9.10 - 30.23
Volume66,517
Avg. Volume151,724
Market Cap628.668M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    MeiraGTx to Host Parkinson’s Disease R&D Day in New York

    LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson’s disease-focused R&D Day on December 13, 2019 from 9:00-11:30 a.m. ET in New York. The program will focus on MeiraGTx’s investigational gene therapy candidate AAV-GAD in development for the treatment of Parkinson’s disease. MeiraGTx’s president and CEO, Alexandria Forbes, Ph.D., will be joined by additional members of the senior leadership team, in addition to leading clinicians and researchers, to discuss the current Parkinson’s disease treatment landscape and results from Phase 1 and Phase 2 clinical trials of AAV-GAD.

  • GlobeNewswire

    MeiraGTx to Present at Upcoming Healthcare Conferences

    LONDON and NEW YORK, Nov. 26, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced.

  • GlobeNewswire

    MeiraGTx Reports Third Quarter 2019 Financial Results

    LONDON and NEW YORK, Nov. 07, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • GlobeNewswire

    MeiraGTx to Present at Upcoming Scientific and Investor Conferences

    LONDON and NEW YORK, Oct. 03, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will.

  • GlobeNewswire

    MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

    MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company’s Phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The Phase 1/2 open-label, multi-center, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with disease-causing variants in the RPE65 gene, a condition that causes severe sight impairment beginning at birth. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability.

  • GlobeNewswire

    MeiraGTx Announces Pricing of Public Offering of Ordinary Shares

    LONDON and NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 3,200,000 of its ordinary shares at a public offering price of $23.50 per share. In addition, MeiraGTx has granted the underwriters a 30-day option to purchase up to an additional 480,000 of its ordinary shares at the public offering price, less underwriting discounts and commissions. BofA Merrill Lynch, Piper Jaffray and Chardan are acting as joint book-running managers of the offering.

  • GlobeNewswire

    MeiraGTx Announces Proposed Public Offering of Ordinary Shares

    LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of $75 million of its ordinary shares. In connection with the offering, MeiraGTx intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering. All of the ordinary shares are being offered by MeiraGTx.

  • GlobeNewswire

    MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    LONDON and NEW YORK, Aug. 07, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • GlobeNewswire

    MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update

    • Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the.

  • GlobeNewswire

    MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency

    LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive data from a Phase 1/2 dose escalation trial of AAV-RPE65, the Company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability. The trial enrolled 15 patients, including nine young adults (aged 16-24 years old) across three dose escalation cohorts, and six children (aged 5-12 years old) in a pediatric expansion cohort.

  • GlobeNewswire

    MeiraGTx Appoints Nicole Seligman to Board of Directors

    LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Directors. Ms. Seligman is an accomplished leader with extensive executive, legal, compliance and governance experience. “We are delighted to welcome Nicole to the MeiraGTx Board of Directors at this exciting time for the company,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

  • GlobeNewswire

    MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference

    LONDON and NEW YORK, May 06, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,.

  • GlobeNewswire

    MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019

    LONDON and NEW YORK, April 25, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster.

  • GlobeNewswire

    MeiraGTx Reports Full Year 2018 Financial Results

    LONDON and NEW YORK, March 26, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.

  • GlobeNewswire

    MeiraGTx to Present at the Barclays Global Healthcare Conference

    LONDON and NEW YORK, March 06, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that.

  • GlobeNewswire

    MeiraGTx Announces $80 Million Private Placement of Ordinary Shares

    MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 5.8 million ordinary shares at a price of $13.80 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $80 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gene therapy assets through clinical development, as well as for general purposes.

  • GlobeNewswire

    MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors

    LONDON and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Martin Indyk to its Board of Directors. Martin Indyk is an American diplomat who has served in senior positions in the U.S. presidential administrations of Clinton, Bush ’43 and Obama.

  • GlobeNewswire

    MeiraGTx to Present at the BIO CEO & Investor Conference

    LONDON and NEW YORK, Feb. 05, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that.

  • PR Newswire

    Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases

    RARITAN, N.J. , Jan. 31, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ: ...

  • GlobeNewswire

    MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases

    MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has entered into a broad strategic collaboration with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize gene therapies for the treatment of inherited retinal diseases (IRDs). Under the agreement, the two companies will collaborate in the clinical development of MeiraGTx’s leading IRD pipeline, including product candidates for achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP).